Perrigo Q4 Earnings Slightly Miss Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy PRGO?
Source: seekingalpha
- Earnings Performance: Perrigo reported a Q4 non-GAAP EPS of $0.77, missing expectations by $0.01, indicating pressure on profitability that could affect investor confidence.
- Revenue Details: The company's Q4 revenue of $1.11 billion, down 2.6% year-over-year, although beating market expectations by $20 million, reflects sluggish sales growth that may impact future market performance.
- Future Outlook: Perrigo's FY2026 'All In' total net sales outlook ranges from -5.5% to -1.5%, demonstrating a cautious stance on future performance that may raise concerns about its long-term growth potential among investors.
- EPS Guidance: The adjusted diluted EPS outlook for FY2026 is set between $2.00 and $2.30, providing specific figures but necessitating attention to market reactions to this guidance and its potential impact on stock prices.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRGO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRGO
Wall Street analysts forecast PRGO stock price to rise
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 13.220
Low
18.00
Averages
20.33
High
23.00
Current: 13.220
Low
18.00
Averages
20.33
High
23.00
About PRGO
Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Perrigo (PRGO) Q4 2025 Earnings Call Transcript
See More
Perrigo Company Q4 2025 Earnings Call Insights
- Market Share Gains: Perrigo achieved over $100 million in new distribution and competitive market share gains in 2025, with the CEO emphasizing that this progress reflects strong engagement with consumers and retailers, despite a generally soft market environment.
- Stable Financial Performance: The company's 2025 GAAP results showed a 2% increase in operating income and a 7% rise in EPS to $2.75, aligning with revised guidance, even as core organic net sales declined by 2%.
- Strategic Transformation Plan: Perrigo announced the introduction of new reporting segments in 2026, including Self-care, Specialty Care, and Infant Formula, to provide clearer performance insights, while also planning a global workforce reduction of approximately 7% over the next two years, with expected annualized pretax savings of $80 million to $100 million.
- Cautious Future Outlook: Management anticipates 2026 to be a
See More
PERRIGO STOCK DROPS 7.4% FOLLOWING Q4 PROFIT DISAPPOINTMENT
- Company Performance: Perrigo shares fell by 7.4% following the announcement of their fourth-quarter results.
- Profit Estimates: The decline in share value was attributed to missing profit estimates for the quarter.
See More
Perrigo Issues 2026 Financial Guidance Amid Losses
- 2026 Financial Outlook: Perrigo projects adjusted earnings per share for fiscal 2026 to be between $2.00 and $2.30, despite an anticipated total net sales decline of 5.5% to 1.5%, indicating significant market challenges and the urgency of strategic adjustments.
- Core Business Focus: The company sets its adjusted earnings per share for core operations at $2.25 to $2.55, with core net sales expected to change between a decline of 3.0% and growth of 1.0%, demonstrating Perrigo's prioritization of resource allocation to navigate market fluctuations.
- Operational Enhancement Program: Perrigo has launched a two-year enterprise-wide operational enhancement program, expecting to reduce approximately 7% of its workforce to improve supply chain and distribution efficiency, thereby strengthening its competitive position in the market.
- Widening Financial Losses: The company reported a net loss of $1.42 billion for the fourth quarter, translating to a loss of $10.22 per share, significantly up from a loss of $44.5 million or $0.32 per share in the prior year, primarily due to goodwill impairment charges, reflecting the financial pressures currently faced by the company.
See More
Perrigo Q4 Earnings Slightly Miss Expectations
- Earnings Performance: Perrigo reported a Q4 non-GAAP EPS of $0.77, missing expectations by $0.01, indicating pressure on profitability that could affect investor confidence.
- Revenue Details: The company's Q4 revenue of $1.11 billion, down 2.6% year-over-year, although beating market expectations by $20 million, reflects sluggish sales growth that may impact future market performance.
- Future Outlook: Perrigo's FY2026 'All In' total net sales outlook ranges from -5.5% to -1.5%, demonstrating a cautious stance on future performance that may raise concerns about its long-term growth potential among investors.
- EPS Guidance: The adjusted diluted EPS outlook for FY2026 is set between $2.00 and $2.30, providing specific figures but necessitating attention to market reactions to this guidance and its potential impact on stock prices.
See More
Perrigo Reports FY2025 Results, Adjusted EPS Outlook Provided
- Financial Performance Overview: Perrigo's net sales for FY2025 were $4.25 billion, a 2.8% decline year-over-year, primarily due to a 2.4% drop in organic sales and a 1.5% impact from divested businesses, indicating pressure in market competition.
- Adjusted EPS Outlook: The company projects its FY2026 'CORE' adjusted EPS to range between $2.25 and $2.55, slightly down from $2.52 in FY2025, reflecting uncertainties in future market conditions.
- Cost Savings Initiative: Perrigo's operational enhancement program is expected to deliver annualized pre-tax savings of $80 million to $100 million by FY2027, aimed at addressing industry pressures and optimizing resource allocation to strengthen long-term competitiveness.
- Goodwill Impairment Impact: The company recognized a goodwill impairment of $1.3 billion in Q4 2025 due to changing market dynamics, resulting in an operating loss of $1.29 billion, highlighting significant financial challenges amid strategic adjustments.
See More
Perrigo (PRGO) Q4 2025 Earnings Call Transcript
See More
Perrigo Company Q4 2025 Earnings Call Insights
- Market Share Gains: Perrigo achieved over $100 million in new distribution and competitive market share gains in 2025, with the CEO emphasizing that this progress reflects strong engagement with consumers and retailers, despite a generally soft market environment.
- Stable Financial Performance: The company's 2025 GAAP results showed a 2% increase in operating income and a 7% rise in EPS to $2.75, aligning with revised guidance, even as core organic net sales declined by 2%.
- Strategic Transformation Plan: Perrigo announced the introduction of new reporting segments in 2026, including Self-care, Specialty Care, and Infant Formula, to provide clearer performance insights, while also planning a global workforce reduction of approximately 7% over the next two years, with expected annualized pretax savings of $80 million to $100 million.
- Cautious Future Outlook: Management anticipates 2026 to be a
See More
PERRIGO STOCK DROPS 7.4% FOLLOWING Q4 PROFIT DISAPPOINTMENT
- Company Performance: Perrigo shares fell by 7.4% following the announcement of their fourth-quarter results.
- Profit Estimates: The decline in share value was attributed to missing profit estimates for the quarter.
See More
Perrigo Issues 2026 Financial Guidance Amid Losses
- 2026 Financial Outlook: Perrigo projects adjusted earnings per share for fiscal 2026 to be between $2.00 and $2.30, despite an anticipated total net sales decline of 5.5% to 1.5%, indicating significant market challenges and the urgency of strategic adjustments.
- Core Business Focus: The company sets its adjusted earnings per share for core operations at $2.25 to $2.55, with core net sales expected to change between a decline of 3.0% and growth of 1.0%, demonstrating Perrigo's prioritization of resource allocation to navigate market fluctuations.
- Operational Enhancement Program: Perrigo has launched a two-year enterprise-wide operational enhancement program, expecting to reduce approximately 7% of its workforce to improve supply chain and distribution efficiency, thereby strengthening its competitive position in the market.
- Widening Financial Losses: The company reported a net loss of $1.42 billion for the fourth quarter, translating to a loss of $10.22 per share, significantly up from a loss of $44.5 million or $0.32 per share in the prior year, primarily due to goodwill impairment charges, reflecting the financial pressures currently faced by the company.
See More
Perrigo Q4 Earnings Slightly Miss Expectations
- Earnings Performance: Perrigo reported a Q4 non-GAAP EPS of $0.77, missing expectations by $0.01, indicating pressure on profitability that could affect investor confidence.
- Revenue Details: The company's Q4 revenue of $1.11 billion, down 2.6% year-over-year, although beating market expectations by $20 million, reflects sluggish sales growth that may impact future market performance.
- Future Outlook: Perrigo's FY2026 'All In' total net sales outlook ranges from -5.5% to -1.5%, demonstrating a cautious stance on future performance that may raise concerns about its long-term growth potential among investors.
- EPS Guidance: The adjusted diluted EPS outlook for FY2026 is set between $2.00 and $2.30, providing specific figures but necessitating attention to market reactions to this guidance and its potential impact on stock prices.
See More
Perrigo Reports FY2025 Results, Adjusted EPS Outlook Provided
- Financial Performance Overview: Perrigo's net sales for FY2025 were $4.25 billion, a 2.8% decline year-over-year, primarily due to a 2.4% drop in organic sales and a 1.5% impact from divested businesses, indicating pressure in market competition.
- Adjusted EPS Outlook: The company projects its FY2026 'CORE' adjusted EPS to range between $2.25 and $2.55, slightly down from $2.52 in FY2025, reflecting uncertainties in future market conditions.
- Cost Savings Initiative: Perrigo's operational enhancement program is expected to deliver annualized pre-tax savings of $80 million to $100 million by FY2027, aimed at addressing industry pressures and optimizing resource allocation to strengthen long-term competitiveness.
- Goodwill Impairment Impact: The company recognized a goodwill impairment of $1.3 billion in Q4 2025 due to changing market dynamics, resulting in an operating loss of $1.29 billion, highlighting significant financial challenges amid strategic adjustments.
See More
